Article ID Journal Published Year Pages File Type
10915903 Nuclear Medicine and Biology 2015 8 Pages PDF
Abstract
111In-EGFt may reduce the adverse effects previously observed in patients administered 111In-hEGF since it is not biologically active, but its lower uptake by BC cells and tumors would limit its effectiveness for treatment of breast cancer.
Keywords
Related Topics
Life Sciences Biochemistry, Genetics and Molecular Biology Cancer Research
Preview
A comparison of non-biologically active truncated EGF (EGFt) and full-length hEGF for delivery of Auger electron-emitting 111In to EGFR-positive breast cancer cells and tumor xenografts in athymic mice
Authors
, , , , , , ,